Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug shows promise in battle against rare blood cancer

NCT ID NCT07033598

First seen Feb 05, 2026 · Last updated May 23, 2026 · Updated 16 times

Summary

This study compares two drugs—pacritinib and hydroxyurea—in adults with advanced chronic myelomonocytic leukemia (CMML), a rare blood cancer. The goal is to see if pacritinib can better control the disease, improve blood counts, reduce spleen size, and ease symptoms. About 66 participants will take one of the two drugs for up to 48 weeks and be monitored for side effects and outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOMONOCYTIC, CHRONIC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact Email: •••••@•••••

  • Mayo Clinic Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-••••

    Contact

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact Email: •••••@•••••

    Contact

  • Winship Cancer Institute at Emory

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.